Beneficial impact of spironolactone in diabetic nephropathy
Open Access
- 1 December 2005
- journal article
- research article
- Published by Elsevier in Kidney International
- Vol. 68 (6) , 2829-2836
- https://doi.org/10.1111/j.1523-1755.2005.00756.x
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive PatientsHypertension, 2005
- Spironolactone prevents early renal injury in streptozotocin-induced diabetic ratsKidney International, 2004
- Aldosterone/salt induces renal inflammation and fibrosis in hypertensive ratsKidney International, 2003
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Effectiveness of Spironolactone Added to an Angiotensin-Converting Enzyme Inhibitor and a Loop Diuretic for Severe Chronic Congestive Heart Failure (The Randomized Aldactone Evaluation Study [RALES])**See Appendix for full list of RALES investigators.The American Journal of Cardiology, 1996
- Mechanisms of enhanced angiotensin II–stimulated signal transduction in vascular smooth muscle by aldosteroneJournal of Cellular Physiology, 1994
- Vasodilation to acetylcholine in primary and secondary forms of human hypertension.Hypertension, 1993
- Asynchronous changes in prorenin and renin secretion after captopril in patients with renal artery stenosis.Hypertension, 1983
- Catecholamine-mediated constrictor effects of aldosterone on vascular smooth muscleLife Sciences, 1982
- Molecular Basis of Proteinuria of Glomerular OriginNew England Journal of Medicine, 1978